Clinical study on saccharomyces boulardii in the treatment of patients with mild to moderate ulcerative colitis

Aim: To investigate the clinical therapeutic efficacy of saccharomyces boulardii(Sb) in combination with mesalazine in patients with mild to moderate ulcerative colitis (UC). Methods: Sixty patients aged 18 to 75 years with mild to moderate UC were divided into two groups, the combination group and the mesalazine group. Clinical remission rate (CRR) was calculated with the formula: CRR= number of complete remission cases + number of effective cases)/all cases. The clinical symptom score (CSS), endoscopic score (ES) and histopathological score (HS) were recorded before and after treatment. Result: After two week's treatment, the CSS in the combination group was significantly decreased (P<;0.05), but in the mesalazine group it showed no significant changes (P>0.05). After four week's treatment, the CSS in both combination group and mesalazine group was significantly decreased(P<;0.05). After 8 week's treatment, the CSS, ES and HS in the combination group were significantly lower than those in the mesalazine group(P<;0.05). CRR in the combination group (46.7%) was significantly higher than that in the mesalazine group (20.0%) after 8 weeks' treatment (P<;0.05). Conclusion: Saccharomyces boulardii in combination with mesalazine is faster and more effective in improving clinical symptoms, endoscopic and histopathological changes in patients with mild to moderate UC than using mesalazine alone.

[1]  J. Söderholm,et al.  Importance of disrupted intestinal barrier in inflammatory bowel diseases , 2011, Inflammatory bowel diseases.

[2]  R. Berg,et al.  Inhibition of Candida albicans translocation from the gastrointestinal tract of mice by oral administration of Saccharomyces boulardii. , 1993, The Journal of infectious diseases.

[3]  Michael A McGuckin,et al.  Intestinal barrier dysfunction in inflammatory bowel diseases. , 2009, Inflammatory bowel diseases.

[4]  C. Manichanh,et al.  Review article: the role of bacteria in onset and perpetuation of inflammatory bowel disease , 2006, Alimentary pharmacology & therapeutics.

[5]  P. Rampal,et al.  Saccharomyces boulardii inhibits secretagogue-mediated adenosine 3',5'-cyclic monophosphate induction in intestinal cells. , 1994, Gastroenterology.

[6]  Luciano G. Fietto,et al.  Intracellular Signal Triggered by Cholera Toxin inSaccharomyces boulardii and Saccharomyces cerevisiae , 1998, Applied and Environmental Microbiology.

[7]  P. Tulkens,et al.  Saccharomyces boulardii upgrades cellular adaptation after proximal enterectomy in rats , 1999, Gut.

[8]  J. Thomas LaMont,et al.  Saccharomyces boulardii Protease Inhibits the Effects of Clostridium difficile Toxins A and B in Human Colonic Mucosa , 1999, Infection and Immunity.

[9]  R G Newcombe,et al.  Transdermal nicotine for active ulcerative colitis. , 1994, The New England journal of medicine.

[10]  Pierre Bourlioux,et al.  Inhibition of in vitro cell adherence of Clostridium difficile by Saccharomyces boulardii. , 2002, Microbial pathogenesis.

[11]  C. Elson,et al.  Experimental models of inflammatory bowel disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the microbiota , 2005, Immunological reviews.

[12]  Mustafa Aldemir,et al.  The effects of Saccharomyces boulardii on bacterial translocation in rats with obstructive jaundice. , 2006, Annals of the Royal College of Surgeons of England.

[13]  F. Shanahan,et al.  Probiotics in inflamatory bowel disease , 2001, Gut.

[14]  S. Dahan,et al.  Saccharomyces boulardii Preserves the Barrier Function and Modulates the Signal Transduction Pathway Induced in Enteropathogenic Escherichia coli-Infected T84 Cells , 2000, Infection and Immunity.

[15]  B. Rembacken,et al.  Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial , 1999, The Lancet.

[16]  P. Gayral,et al.  Inhibitory activity of saccharomyces yeasts on the adhesion ofEntamoeba histolytica trophozoites to human erythrocytes in vitro , 2004, Parasitology Research.

[17]  J. Cebra,et al.  Influences of microbiota on intestinal immune system development. , 1999, The American journal of clinical nutrition.

[18]  K. Ewe,et al.  Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD) , 1995, Clinical and experimental immunology.

[19]  S. Dahan,et al.  Implication of Mitogen-Activated Protein Kinases in T84 Cell Responses to Enteropathogenic Escherichia coli Infection , 2001, Infection and Immunity.

[20]  Silvia C Resta,et al.  Effects of probiotics and commensals on intestinal epithelial physiology: implications for nutrient handling , 2009, The Journal of physiology.

[21]  S. Salminen,et al.  Probiotics: a role in the treatment of intestinal infection and inflammation? , 2002, Gut.

[22]  C. Pothoulakis,et al.  Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum , 1996, Infection and immunity.

[23]  L. Hale,et al.  Bacterial-mucosal interactions in inflammatory bowel disease: an alliance gone bad. , 2008, American journal of physiology. Gastrointestinal and liver physiology.

[24]  C. Pothoulakis,et al.  Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum. , 1993, Gastroenterology.